Researchers have found that specific mutations in the dystrophin gene correlate with earlier or later onset of cardiac muscle degeneration.
This story was updated Oct. 6, 2010.
In many forms of muscular dystrophy, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), weakness and degeneration of the cardiac muscle can be a major part of the disease, and one that frequently shortens life.
Now, doctors at Ohio State University and Nationwide Children's Hospital in Columbus, Ohio, as well as Washington University in St. Louis and the University of Utah in Salt Lake City, have identified specific mutations in the dystrophin gene that predict whether heart muscle weakness (cardiomyopathy) will occur earlier or later in the course of BMD.
The findings may help with predicting the disease course and may shed light on the complex mechanisms underlying cardiac degeneration in DMD or BMD. They also may lead to earlier and perhaps better treatments for this type of problem.
Monitoring of heart function is an important part of the care of young men with DMD or BMD.
Federica Montanaro at Nationwide Children's Hospital coordinated a multicenter team that included several MDA-associated physicians. Findings were published in the December 2009 issue of Circulation: Cardiovascular Genetics.
The researchers studied the dystrophin gene mutations and the clinical medical records of 78 people with either X-linked dilated cardiomyopathy or BMD-associated cardiomyopathy. (DMD patients were not part of this study.)
They found that different mutations could cause the median age at the onset of cardiomyopathy to range from the mid-20s to the mid-40s.
About BMD molecular mechanisms
BMD is a disease of skeletal and cardiac muscle that results from any of a number of mutations in the X-chromosome gene for the dystrophin protein, which normally plays a crucial role in both muscle tissues. In BMD, there is some dystrophin produced, but it's either deficient in quantity or quality. In DMD, dystrophin mutations result in the total or nearly total loss of dystrophin.
In BMD, cardiac abnormalities can be severe enough to require a heart transplant, even while skeletal muscle loss may range from moderate to mild to absent.
(Note: Patients with dystrophin mutations and cardiac muscle degeneration who maintain normal skeletal muscle strength are said to have "X-linked dilated cardiomyopathy," rather than Becker MD.)
The dystrophin protein is a ropelike molecule that's located near the cell membrane in heart and skeletal muscle cells. It's divided into regions called "domains," which serve different functions.
The protein is attached to the inside of the cell at one end, called the "actin-binding domain," and to a cluster of proteins nestled in the membrane on the other end, before looping back to the inside of the cell.
In between the actin-binding domain and the part that links to the membrane is a springy, ropey structure made of a series of repeating spirals called the "rod domain." Although it's straight, like a rod, it's also flexible, and it's believed to provide support and shock absorption for the membrane.
About the new findings
Previous studies have found that mutations in the dystrophin gene that affect the rod domain usually cause relatively mild skeletal muscle degeneration, compared to mutations that affect either end of the dystrophin protein outside the rod domain.
But the new findings show that mutations in the rod domain can have unexpectedly severe effects on the ability of dystrophin to protect the heart muscle.
The researchers found that patients with dystrophin mutations and cardiomyopathy, with or without skeletal muscle involvement, had mutations affecting the rod domain or the actin-binding domain.
Those with mutations in gene sections known as exons 45 to 49 that affected the rod domain and preserved a portion called hinge 3 had a median age of onset of cardiomyopathy of either 26 or 36 years, depending on whether the mutation disrupted the dystrophin protein structure.
Those with mutations in gene sections known as exons 45 to 55 that affected the rod domain but did not preserve hinge 3 had a median age of onset of cardiomyopathy of 43 years.
The median age of onset for cardiomyopathy for those with mutations in exons 2 to 9, affecting the actin-binding domain, was 23.
About MDA's role
Although MDA did not fund this study directly, several of the study's authors are longtime MDA-associated clinicians and/or research grantees.
John Kissel and Jerry Mendell at Nationwide Children's Hospital and Ohio State University are co-directors of the MDA clinic at Nationwide and have received significant MDA funding for research over many years. Mendell has current MDA support to study cardiomyopathy in DMD. Kevin Flanigan, who was at the University of Utah in Salt Lake City until 2009 and then moved to Nationwide Children's Hospital, is a former MDA research grantee; and Alan Pestronk directs the MDA clinic at Washington University in St. Louis and has received previous MDA research support.
Meaning for people with BMD and DMD
The new findings will help doctors predict the onset of cardiomyopathy based on a patient's specific dystrophin mutation and allow them to consider cardioprotective treatments earlier in the disease course.
In addition, the findings have implications for therapy development. The study sheds light on which parts of the dystrophin gene and protein are necessary for cardiac function, while most studies to date have focused on skeletal muscle function. That will be important to know as scientists continue to develop miniaturized versions of the dystrophin gene for gene therapy applications and develop other strategies that are likely to result in synthesis of shortened dystrophin protein molecules.
Families affected by BMD or DMD who would like to be part of an ongoing study to determine the relationship between disease course and dystrophin mutation site can enroll in the United Dystrophinopathy Project, an ongoing study funded by the National Institutes of Health. See the United Dystrophinopathy Project and the Online Duchenne and Becker Muscular Dystrophy Patient Registry and/or the United Dystrophinopathy Project.
Editor's note 10/6/10: The September 2010 neuromuscular disease research podcast from Nationwide Children's Hospital in Columbus, Ohio, is an interview with Nationwide neurobiologist Federica Montanaro on cardiomyopathy in BMD. You can listen to this podcast at This Month in Muscular Dystrophy.